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Work-up as well as management of patients with non-
small cell lung cancer (NSCLC) and clinically suspicious 
mediastinal lymph nodes (c-N2) should consider current 
guidelines (1), although the final implementation differs 
between several institutions and countries.
The authors have selected upfront surgery without prior 
invasive or non-invasive mediastinal staging and assessed 
the short-term outcome of robotic assisted surgery (RATS) 
in comparison to thoracotomy in a multicenter randomized 
controlled trial (2). No meaningful differences were found 
in most of the parameters, besides significant differences in 
intraoperative blood loss, drainage time, and postoperative 
pain (2). 
The question, whether these short-term outcome 
parameters are relevant for the evaluation of treatment 
quality and efficacy of patients with locally advanced lung 
cancer, may lead to a controversial discussion, particularly 
in relation to the more relevant long-term outcome results. 
Patients and doctors most likely agree that overall- (OS) 
and disease-free survival (DFS) in a lung cancer operation 
is most important and side effects from surgery such as 
drainage and hospitalisation time are clearly less meaningful. 
OS and DFS after surgery for clinical stage III (N2) depends 
on two main factors, such as complete resection of the 
tumor, a so called R0-resection and definitive pathological 
mediastinal lymph node stage. The latter guides the need 
for adjuvant therapy including adjuvant chemotherapy, 
targeted treatment, immunotherapy, and radiotherapy. OS 
and DFS were not assessed in the reported trial but R0 
and R1 resection were equal in both groups indicating that 
radicality of surgery was comparable in both groups, and 
independent from the approach. This was found already 
in multiple studies before, which compared video-assisted 
thoracoscopic surgery (VATS) with thoracotomy in early 
stage lung cancer up to a tumor size of less than 3 cm 
(3,4). Furthermore, these studies showed that survival after 
resection was comparable for both approaches (5-10). In 
some studies, comprehensive reviews and meta-analyses, 
VATS was even comparing favorably to thoracotomy with 
survival advantage for VATS procedure.
Two published comparisons of long-term oncologic 
outcomes of robotic lobectomy for early-stage NSCLC 
versus VATS and open thoracotomy approach show that 
RATS lobectomy was associated with durable freedom 
of recurrence and long-term survival equivalent to those 
achieved with VATS and the traditional open thoracotomy 
approach. As presented by the Italian group of Veronesi 
et al., RATS approach for locally advanced NSCLC with 
clinically evident or occult N2 is safe and feasible with 3- 
and 5-year OS at 61.2% and 49% respectively (11).
In term of radical R0-resection of early stage lung cancer 
with RATS compared with VATS, there were also no quality 
issues in the literature and comparison between minimally 
invasive (RATS and VATS) versus open lobectomy of locally 
advanced NSCLC achieved a similar R0 resection rate 
between the groups (12).
The second key issue of an oncologically correct lung 
cancer operation is the extent of hilar and mediastinal 
lymph node clearance. The number of lymph nodes and the 
number of lymph node stations resected represents figures 
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of lymph adenectomy completeness. The pathological 
result may lead to recommendations for or against adjuvant 
therapy. In addition, in this regard, both study arms showed 
the same number of investigated lymph nodes. Since all 
patients had upfront surgery without induction chemo- or 
chemoradiation and the lymph node removal extent was 
limited to resectable ones in this trial, the result is not a 
surprise. It has been shown also in many series comparing 
VATS with thoracotomies (4,8,13-16) that lymph node 
resection can be done in at least equal quality using the 
minimal invasive approach. RATS compared to VATS 
came to similar results (17-19). Furthermore, Merritt and 
colleagues show, that mean numbers of total lymph nodes 
and N2 lymph nodes were significantly higher in the 
robotic lobectomy group (P<0.0001) (20).
Many centers would assess enlarged mediastinal 
lymph nodes by EBUS or mediastinoscopy and in case of 
histologically proven mediastinal disease would initiate 
neoadjuvant chemo- or chemoradiation prior to resection. 
Surgery thereafter is occasionally more difficult because 
the dissection planes may be fused and lymph nodes may 
become adherent to vessels (such as v. cava, pulmonary 
vessels) or the trachea. It would be interesting to compare 
the open technique with RATS after neo-adjuvant therapy 
when downstaging occurred and the dissecting planes 
fibrous and lymph nodes stick to vessels, airways, and 
esophagus. The procedure is then more of a challenge 
and patients undergoing RATS lobectomy after induction 
chemotherapy with or without radiation therapy may 
be at greater risk for recurrent laryngeal nerve injury, 
tracheal/bronchial injury, and pulmonary embolism (21). 
Furthermore, as presented by Veronesi and colleagues, 
on robotic resection of stage III lung cancer patients after 
induction chemotherapy, required in 15% conversion and 
12% patients developed grade III or IV postoperative 
complications (11).
Intraoperative blood loss was significantly different when 
comparing the two surgical approaches. The question comes 
up, if a difference of 80 mL is clinically meaningful or not. 
Blood loss has a negative influence on OS after lung cancer 
operations (22). However, only when the amount of blood 
loss is larger than 80 mL a relevant impact on the immune 
system may occur. On the other hand, a blood loss of only 
80 mL in the RATS group may be an indicator, that RATS 
allows very precise and most atraumatic surgery, which is 
often stated by RATS surgeons. The reason includes facts 
such as the excellent 3D view, instruments which allow a 
precise dissecting technique, and possible also the fact, that 
a surgeon needs to avoid even the smallest bleeding in order 
to have a good view and control of the operation.
Drainage time and the amount of drainage fluid differed 
statistically between the groups but with a relatively 
minor clinical meaning. The same can be said for pain 
management. Early postoperative pain was clearly less in 
RATS treated patients, which is an advantage. But, the pain 
in the thoracotomy group seems to be manageable looking 
at the difference in the visual analog scale. 
What can we finally conclude from this randomized 
trial comparing RATS with thoracotomy in c-N2 NSCLC. 
RATS allows a safe and radical procedure also in locally 
advanced lung cancer, at least when upfront surgery without 
neoadjuvant treatment is used. The latter needs to be 
further evaluated. Since safety and radicality are the key 
elements of all cancer operations, the most important goal 
is achieved. Secondary factors such as early postoperative 
pain, drainage time, and intraoperative blood loss favor 
the minimal-invasive approach by RATS—as previously 
shown for VATS. As a word of caution, safety and quality 
of surgery depends heavily on the surgeon’s experience and 
technique and this trial was performed in hospitals with 
high case volumes und experienced surgeons. They have to 
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